This report identifies the global perennial allergic rhinitis market size in for the year 2014-2016, and forecast of the same for year 2021. It also highlights the potential growth opportunities in the coming years, while also reviewing the market drivers, restraints, growth indicators, challenges, market dynamics, competitive landscape, and other key aspects with respect to global perennial allergic rhinitis market.
Geographically Europe dominated global perennial allergic rhinitis market, because of large population of perennial allergic rhinitis patients. Asia Pacific is projected to have fastest growth, owing to rapidly increasing population, rise in consumer awareness for disease diagnosis and its treatment, modernizing healthcare infrastructure and growing medical tourism industry in developing nations such as China, and India in this region. Among all the treatment, antihistamines have the highest market share in global perennial allergic rhinitis market.
This report segments global perennial allergic rhinitis market on the basis of treatment, diagnosis, and regional market as follows:
Perennial Allergic Rhinitis Market, By Treatment: Steroids, Antihistamines, Allergen Immunotherapy Formulations, Decongestants, and Other Treatments
The report has focused study on perennial allergic rhinitis market by basis of diagnosis such as: Radio Allergo Sorbent Testing (RAST), Blood Test, Patch Test, Skin Prick Test, and Allergen Sensitivity Test
This report has been further segmented into major regions, which includes detailed analysis of each region such as: North America, Europe, Asia-Pacific (APAC), and Rest of the World (RoW) covering all the major country level markets in each of the region
This report identifies all the major companies operating in the perennial allergic rhinitis market. Some of the major companies’ profiles in detail are as follows:
Teva Pharmaceutical Industries Ltd.
Merck & Co., Inc.
Hanmi Pharmaceuticals, Inc.
Sumitomo Pharma Co.
Hisamitsu Pharmaceutical Co.
Please Note: The report is to be delivered in 1-2 working days after an order is placed.
2. Executive Summary
3. Market Landscape
3.1. Market Share Analysis
3.2. Comparative Analysis
3.3. Product Benchmarking
3.4. End User Profiling
3.5. Top 5 Financials Analysis
4. Perennial Allergic Rhinitis Market– Market Forces
4.1.1. Development of new and more effective products and formulations
4.1.2. Rise in the awareness regarding perennial allergic rhinitis
4.1.3. Increasing population of perennial allergic rhinitis patients
4.1.4. Environmental changes and changes in lifestyle
4.2.1. Higher cost of research and development
4.2.2. Risk of side effects
4.3.1. Emerging economies
4.3.2. Increase in adoption of perennial allergic rhinitis treatment
4.5. Porter’s Five Forces Analysis
4.5.1. Bargaining Power of Suppliers
4.5.2. Bargaining Power of Buyers
4.5.3. Threat of New Entrants
4.5.4. Threat of Substitutes
4.5.5. Degree of Competition
5. Perennial Allergic Rhinitis Market– Strategic Analysis
5.1. Value Chain Analysis
5.2. Pricing Analysis
5.3. Opportunities Analysis
5.4. Product/Market Life Cycle Analysis
5.5. Suppliers and Distributors
6. Perennial Allergic Rhinitis Market, By Treatment
6.3. Allergen Immunotherapy Formulations
6.5. Other Treatments
7. Perennial Allergic Rhinitis Market, By Diagnosis
7.1. Radio Allergo Sorbent Testing (RAST)
7.2. Blood Test
7.3. Patch Test
7.4. Skin Prick Test
7.5. Allergen Sensitivity Test
8. Perennial Allergic Rhinitis Market, By Geography
8.1.7. Rest of Europe
8.2. Asia Pacific
8.2.4. South Korea
8.2.5. Rest of Asia-Pacific
8.3. North America
8.4. Rest of the World (RoW)
8.4.2. Rest of RoW
9. Perennial Allergic Rhinitis – Market Entropy
9.2. Technological Developments
9.3. Merger & Acquisitions, and Joint Ventures
9.4. Supply- Contract
10. Company Profiles (Overview, Financials, SWOT Analysis, Developments, Product Portfolio)
10.1. Teva Pharmaceutical Industries Ltd.
10.2. Merck & Co., Inc.
10.3. Hanmi Pharmaceuticals, Inc.
10.4. Sumitomo Pharma Co.
10.5. Hisamitsu Pharmaceutical Co.
10.6. Alcon Inc
10.8. Genentech, Inc.
10.9. Pfizer, Inc.
10.10. Novartis AG
*More than 40 Companies are profiled in this Research Report, Complete List available on Request*
"*Financials would be provided on a best efforts basis for private companies"
11.3. Research Methodology
11.5. Compilation of Expert Insights